Abstract
Impaired glucose-stimulated insulin secretion (GSIS) is a hallmark of type-2 diabetes. However, cellular signaling machineries that control GSIS remain incompletely understood. Here, we report that β-klotho (KLB), a single-pass transmembrane protein known as a co-receptor for fibroblast growth factor 21 (FGF21), fine tunes GSIS via modulation of glycolysis in pancreatic β-cells independent of the actions of FGF21. β-cell-specific deletion of Klb but not Fgf21 deletion causes defective GSIS and glucose intolerance in mice and defective GSIS in islets of type-2 diabetic mice is mitigated by adenovirus-mediated restoration of KLB. Mechanistically, KLB interacts with and stabilizes the cytokine receptor subunit GP130 by blockage of ubiquitin-dependent lysosomal degradation, thereby facilitating interleukin-6-evoked STAT3–HIF1α signaling, which in turn transactivates a cluster of glycolytic genes for adenosine triphosphate production and GSIS. The defective glycolysis and GSIS in Klb-deficient islets are rescued by adenovirus-mediated replenishment of STAT3 or HIF1α. Thus, KLB functions as a key cell-surface regulator of GSIS by coupling the GP130 receptor signaling to glucose catabolism in β-cells and represents a promising therapeutic target for diabetes.
Original language | English |
---|---|
Pages (from-to) | 608–626 |
Number of pages | 19 |
Journal | Nature Metabolism |
Volume | 4 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2022 |
Scopus Subject Areas
- Physiology (medical)
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cell Biology
User-Defined Keywords
- Animals
- Cytokine Receptor gp130/genetics
- Diabetes Mellitus, Experimental
- Glucose/metabolism
- Glycolysis
- Insulin Secretion
- Mice